Find out which Indian University was the first to teach biotechnology and why it was important for science and education in ...
Spanish researchers discover AlCas12a, a groundbreaking enzyme for next-generation gene editing.The protein, discovered in wastewater, is smaller, ...
The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...
Fully automated, ultra-high-volume line providing sub-second cycle time, medical-grade precision, and scalable capacity ...
Quantumzyme Corp. (OTC: QTZM), a biotransformation company focused on enzyme-based solutions for pharmaceutical manufacturing, today announced that it plans to attend the 2026 BIO International ...
By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...
GlobalData on MSN
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership
Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.
Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly ...
Eli Lilly plans to expand its hearing loss therapy pipeline by collaborating with Seamless Therapeutics to apply the company’s next-generation gene-editing approach, based on programmable recombinases ...
Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...
This year, sales of Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity ...
The agreement with Seamless is the latest in a series of purchases and partnerships Lilly has established to build a pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results